We are a full service Clinical CRO based in California with office in India and supporting global bio-pharmaceutical and medical device companies. We offer clinical development services for NCE molecules, 505(b)2 and complex generics products requiring patient based clinical studies as part of ANDA/NDA submission. | We are a comprehensive Clinical Contract Research Organization (CRO) headquartered in California, with an additional office in India, providing support to global biopharmaceutical and medical device firms. Our services encompass clinical development for New Chemical Entity (NCE) molecules, 505(b)(2) pathways, and intricate generic products necessitating patient-centric clinical trials as components of ANDA/NDA submissions. Furthermore, we cater to pharmaceutical companies, assisting them with regulatory necessities for both pre-Investigational New Drug (pre-IND) and Investigational New Drug (IND) submissions. | Founded in 2010, CBCC Global Research is a highly regarded full-service clinical CRO, with expertise in innovator, specialty generics, biosimilar and regulatory pathways, across several core therapeutic areas. CBCC provides a suite of high-quality services across multiple mission-critical, specialized functions, including Clinical Operations, Site management, Patient recruitment, biometrics, regulatory services, and scientific and medical writing, for a wide range of study types for the US, India, and Australia execution.
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
BIOTECHNOLOGY VALLEY
The Biotechnology Industrialists’ Association (BİYOSAD) aims to drive human development via innovative, high value-added products and services and is establishing the Biotechnology Valley within the Biotechnology Specialized Industrial Zone (BİOSB) in Istanbul. This project aspires to situate Turkey among the world’s leading biotechnology hubs. Biotechnology Valley, positioned in strategically located Tuzla, Istanbul, is a comprehensive initiative designed to create a specialized biotechnology ecosystem. The project aims to boost Turkey’s global presence in the biotechnology market through strong collaborations between business, academia, and the government. It spans 2.7 million square meters and will feature technology development zones, R&D centers, testing and calibration labs, patent offices, and specialized biotechnology schools. Our goal is to enhance global export potential by fostering domestic production of high value-added biotechnology products. We prioritize guiding industry and academia toward innovative collaboration, exploring nature’s possibilities in light of science. Our mission extends beyond meeting current demands to making a positive impact for future generations through sustainable and collaborative efforts. Biotechnology Valley is dedicated to enabling breakthrough technologies in the sector and hosting research that benefits society, adding value to both science and business. We are committed to providing a safe, innovative, and supportive business environment for all sector stakeholders. Join us as a partner in transforming Türkiye and the world into a leading biotechnology center. | Biotechnology Valley is a strategic technology and innovation ecosystem established under the leadership of the Biotechnology Industrialists Association (BIYOSAD) to lead Türkiye’s vision in biotechnology across science, technology, and production. Bringing together the public sector, industry, academia, and investors, the Valley aims to build a high–value-added, sustainable, and globally competitive biotechnology infrastructure. Located in Tepeören, Istanbul, and spanning approximately 2.7 million square meters, Biotechnology Valley is one of Türkiye’s most comprehensive biotechnology initiatives. With its advanced R&D centers, technology development zones, modern manufacturing facilities, and shared infrastructure, the Valley is designed as an integrated hub for local and international companies operating in pharmaceuticals, biotechnology products, medical technologies, and advanced life sciences. Biotechnology Valley is not only a center for production and R&D, but also a living and innovation ecosystem with sustainability at its core. The project prioritizes energy-efficient infrastructure, renewable energy solutions, water efficiency practices, integrated waste management systems, and comprehensive strategies to reduce carbon footprint. This approach positions biotechnology production in harmony with nature and with a strong sense of responsibility toward future generations. The Valley offers a collaborative, innovative, and scalable ecosystem for a wide range of stakeholders, from start-ups and research institutions to global players and investment funds. Through its open innovation approach, Biotechnology Valley promotes knowledge sharing and co-creation, aiming to integrate Türkiye’s biotechnology potential into the global value chain. With its robust infrastructure, sustainability-driven framework, and international vision, Biotechnology Valley continues to advance with determination toward becoming a regional and global center for biotechnology.
Biopôle SA
Biopôle Lausanne is one of the largest life sciences campus in Europe, hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne, Switzerland (www.biopole.ch). It offers a world-class combination of modern infrastructure (134,000 sqm of office/lab space), added value services, an extensive network, innovation and funding programmes, and unparalleled community engagement where members can thrive and bring science to life. Biopôle houses 130+ life sciences companies, including 50 biotech/pharma such as Ferring, Roche, Ichnos, etc. and world-class research organizations (Lausanne University Hospital (CHUV), University of Lausanne (UNIL), the Ludwig Institute for Cancer Research etc.), a life science incubator (StartLab), ready-to-move-in private labs (Superlab), a Digital Health Hub (DH2) enabling the emergence of outstanding innovation for the betterment of healthcare. Join Biopôle.
BioProduction by SEKISUI
BioProduction by Sekisui offers CDMO services for the biopharmaceutical industry. Our UK facility has over 40 years fermentation and purification experience with proteins. Our microbial expression and process optimization together with our production experience helps smooth technical transfer and process scale up. We have process and analytical development capabilities for enzymes, plasmids, antibody fragments and other proteins. We are completing a $19M cGMP manufacturing expansion for drug substance manufacturing in 2024. We are co-exhibiting with Sekisui America Corporation, the regional HQ of global chemical manufacturer Sekisui Chemical, located in the United States. They work on developing solutions for the life science industry, with a focus on cell and gene therapy. Products include cell culture consumables such as state-of-the-art cell culture media and scaffolds. Chemically defined scaffold (CDS) can be used for the serum-free culture of pluripotent stem cells (iPSCs, ESCs, MSCs and so on). It is a synthetic polymer that can be stored at room temperature, pre-coated on a variety of surfaces and can be adapted to automated culture equipment. It can establish a safe and stable cell culture process and can lead to reduction in total cell culture cost. We are looking for partners in the field of cell and gene therapy such as academic organizations, pharmaceutical companies and automated bioreactor manufacturers who can act as joint development partners in adapting our products for their pipeline. | BioProduction by SEKISUI – A Specialized CDMO within the SEKISUI Medical Group BioProduction by SEKISUI is the biomanufacturing CDMO division of SEKISUI Diagnostics, part of the globally recognized SEKISUI Medical Group.BioProduction by SEKISUI describes SEKISUI’s contract service offering as a microbial fermentation focused CDMO with over 40 years of expertise in microbial biomanufacturing. We specialize in microbial fermentation, protein purification, and downstream processing for enzymes, recombinant proteins, ligands, antibody fragments, and plasmids. With experience in E. coli, Pichia pastoris, Bacillus, Streptococcus, Streptomyces, fungi, and yeast, we provide seamless process transfer and scale-up to meet diverse biopharmaceutical needs. Our UK-based facility features fermentation capacities ranging from 2L to 5,000L, advanced chromatography techniques, and lyophilization capabilities. While cGMP capacity expansion for clinical-grade drug substance manufacturing is in progress, we adhere to ISO 9001 standards, ISO 8 cleanroom classifications, and environmental safety regulations, ensuring quality and reliability. Driven by Kaizen-based continuous improvement and a zero-emissions sustainability commitment, BioProduction by SEKISUI partners with global leaders to deliver scalable, high-quality biomanufacturing solutions. Learn more at bioproduction-sekisui.com. SEKISUI CHEMICAL Group has been driving innovation since 1947. Today, we’re committed to developing cell culture solutions that make cell culture more reliable, scalable, and efficient. Our flagship product, Ceglu™, is a chemically defined, synthetic matrix that provides a stable, feeder-free environment for stem cells (iPSCs, ESCs, MSCs). Designed for consistency and ease of use, Ceglu™ reduces variability and offers the convenience of room-temperature storage. Ceglu™ is available in two formats: pre-coated culture plates for immediate use and a coating solution that can be applied to automated culture systems and bioreactors for seamless large-scale production. With a focus on advancing regenerative medicine, SEKISUI collaborates with industry leaders to deliver innovative solutions that meet the evolving needs of the cell and gene therapy field and help achieve shared goals. Learn more at https://www.sekisui-cell.jp/en/
BioAro
BioAro Inc. is a leading biotechnology company specializing in whole genome sequencing and advanced genetic analysis. With a strong commitment to personalized medicine, BioAro leverages cutting-edge genomic technologies to provide individuals, healthcare professionals, and researchers with comprehensive insights into genetic health, disease predisposition, and personalized wellness strategies. At the core of BioAro’s services is its whole genome sequencing platform, which delivers high-precision genetic data that empowers users to make informed health decisions. The company’s offerings extend beyond raw data by providing advanced interpretation through proprietary bioinformatics pipelines and AI-driven analytics. By transforming complex genetic information into actionable insights, BioAro enables early disease detection, risk assessment, and tailored treatment recommendations. BioAro is dedicated to bridging the gap between genomic science and real-world application by making genetic testing accessible and understandable. Its services cater to a diverse clientele, including individuals interested in proactive health management, clinicians seeking precision medicine solutions, and researchers aiming to advance genetic discoveries. The company also collaborates with pharmaceutical and healthcare organizations to support drug development and personalized therapeutics. With a focus on innovation and data security, BioAro upholds the highest standards of accuracy and confidentiality. Its state-of-the-art sequencing facilities adhere to rigorous quality controls, ensuring reliable results that users can trust. As the demand for personalized medicine grows, BioAro continues to expand its capabilities, staying at the forefront of genomic advancements to improve health outcomes and revolutionize the future of healthcare. | BioAro Inc., established in 2021, is a Canadian biotechnology company headquartered in Calgary, Alberta. The company specializes in precision health, health span, and longevity, integrating genomics, artificial intelligence (AI), and blockchain technologies to deliver personalized healthcare solutions. BioAro’s mission is to revolutionize personalized healthcare through its cutting-edge technologies, including the BioPhenome Lab, BioHealth software solutions, Biospan clinics, and biotech devices. The company’s vision focuses on extending human healthspan by integrating innovative approaches for a healthier future. BioAro operates internationally, with Headoffice in Calgary, Canada; and offices in Dubai, United Arab Emirates; and Almelo, The Netherlands, and United Kingdom reflecting its commitment to making personalized medicine accessible worldwide. BioAro aims to transform healthcare from reactive disease management to proactive health optimization, empowering individuals to take control of their health and well-being. | BioAro Inc. is a Calgary-based precision health biotechnology company advancing real-time, AI-driven multi-omics solutions for personalized medicine. Its PanOmiQ™ platform integrates genomic, epigenomic, pharmacogenomic, microbiome, and clinical data to deliver rapid, scalable insights that support early disease detection, tailored treatment strategies, and predictive healthcare. BioAro’s ecosystem improves clinical decision-making and expands precision medicine markets.
Beth Bioinformatics Co., Ltd
Beth Bioinformatics (BethBio) is a solution provider for novel vaccine development. We invent and deliver innovative solutions to empower vaccine manufacturers design effective antigens, improve vaccine performance and streamline clinical trials. BethBio holds the world’s most accurate method Beth-1 for predicting future evolution of influenza virus. By modelling viral mutations, we design vaccine antigens that generate higher vaccine efficacy (VE) against future circulating strains and a longer protection period. We also cover other pathogens such as SARS-CoV-2, RSV and Monkeypox. BethBio has also developed a first-of-its-kind computation platform for accurate VE estimation without first requiring vaccination. It provides strategic benefits throughout the vaccine development cycle, from supporting antigen optimization to refining clinical trial designs and product planning. The technology has been used to support clients in drug applications and was accepted as supporting evidence by regulatory authority. Our PCO codon optimization preserves correct protein conformation while optimizing expression and other properties, outperforms the best alternative methods in various platforms and is adopted by vaccine developers in multiple countries. We also offer a unique epitope screening system through genome stability evaluation, which facilitates the identification of broadly reactive epitopes and development of therapeutic vaccines. We look forward to collaborating with you.
Arochi & Lindner
Arochi & Lindner: Premier Legal Solutions for the Life Sciences and Pharmaceutical Industries With more than 30 years of experience, Arochi & Lindner is a leading law firm in Mexico and Spain, known for its excellence in Intellectual Property, Litigation, and Regulatory Advisory. Our Life Sciences practice stands out as one of the most robust in the market, providing strategic legal solutions for companies in the pharmaceutical, biotechnology, medical device, food, cosmetics, and agricultural sectors. We recognize that the Life Sciences sector is constantly evolving and encounters complex regulatory challenges. That’s why we offer thorough legal counsel that covers a wide range of services, including trademark and patent registration, obtaining sanitary authorizations from COFEPRIS, drafting licensing agreements, ensuring regulatory compliance, handling patent litigation, and navigating public procurement processes. Our multidisciplinary team — which includes attorneys, chemists, engineers, and biotechnologists — combines technical and legal expertise to provide practical and efficient solutions aligned with our clients’ business goals. We have successfully represented drug companies in high-profile patent disputes and have managed groundbreaking innovations, such as the first microorganism deposit at Mexico’s National Center for Genetic Resources (CNRG). At Arochi & Lindner, we don’t just protect innovation — we empower it. Our mission is to act as a strategic partner for companies transforming health, technology, and quality of life through science.
Ardigen
Ardigen is your end-to-end trusted partner in the data-to-insights enablement journey that powers modern, AI-data-driven drug discovery. We help life science organizations transform fragmented, multimodal biomedical data into AI-ready foundations, actionable insights, and scalable discovery workflows. Our approach bridges the gap between data potential and discovery impact, grounded in a science-first model that starts with the biological question and aligns every step to measurable, real-world scientific outcomes. | Ardigen, a world-leading AI CRO, stands at the forefront of enabling AI transformation for the biotech and pharmaceutical sectors. Our objective is to increase the probability of success in the drug development process. We utilize our advanced platforms and deep expertise to turn vast amounts of data into pivotal, ready-to-use scientific insights. Leveraging our expertise, we also enhance the infrastructure that allows our clients to integrate and utilize these capabilities seamlessly within their organizations. | Ardigen is a leading AI Contract Research Organisation (CRO) dedicated to increasing the success rate of drug discovery. Recognized among the top 5% of AI in drug discovery companies worldwide, Ardigen integrates expertise in biology, bioinformatics, machine learning, and software engineering to deliver advanced computational solutions exclusively tailored for the biotechnology and pharmaceutical sectors. Over the past 10 years, we have earned the trust of over 120 clients, including 15 major pharmaceutical companies, by providing exceptional in silico research and data engineering services.